MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Danaher Corp

Suletud

SektorTervishoid

199.98 -2.4

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

199.7

Max

204.69

Põhinäitajad

By Trading Economics

Sissetulek

268M

1.1B

Müük

738M

6.5B

P/E

Sektori keskmine

38.752

63.778

Aktsiakasum

2.14

Dividenditootlus

0.62

Kasumimarginaal

16.611

Töötajad

61,000

EBITDA

-230M

1.4B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+31.35% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.62%

2.39%

Järgmine tulemuste avaldamine

22. apr 2025

Järgmine dividendimakse kuupäev

25. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-16B

147B

Eelmine avamishind

202.38

Eelmine sulgemishind

199.98

Uudiste sentiment

By Acuity

25%

75%

62 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Danaher Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. veebr 2025, 12:54 UTC

Tulu

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29. jaan 2025, 11:44 UTC

Tulu

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22. okt 2024, 10:35 UTC

Tulu

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

23. juuli 2024, 10:55 UTC

Tulu

Danaher Expects 3Q Core Sales Drop, Backs 2024 Guidance

29. jaan 2025, 15:25 UTC

Market Talk
Tulu

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29. jaan 2025, 13:56 UTC

Peamised uudised
Tulu

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29. jaan 2025, 11:08 UTC

Tulu

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29. jaan 2025, 11:07 UTC

Tulu

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29. jaan 2025, 11:07 UTC

Tulu

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29. jaan 2025, 11:02 UTC

Tulu

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29. jaan 2025, 11:01 UTC

Tulu

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29. jaan 2025, 11:01 UTC

Tulu

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q Cont Ops EPS $1.49 >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q Net $1.09B >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q EPS $1.49 >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q Adj EPS $2.14 >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q Sales $6.5B >DHR

22. okt 2024, 10:02 UTC

Tulu

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22. okt 2024, 10:02 UTC

Tulu

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

22. okt 2024, 10:01 UTC

Tulu

Danaher Sees 4Q Adjusted Core Revenue Down Low-Single Digits >DHR

22. okt 2024, 10:00 UTC

Tulu

Danaher 3Q Operating Cash Flow $1.5B, Adjusted Free Cash Flow $1.2B >DHR

22. okt 2024, 10:00 UTC

Tulu

Danaher 3Q Sales $5.8B >DHR

22. okt 2024, 10:00 UTC

Tulu

Danaher 3Q EPS $1.12 >DHR

22. okt 2024, 10:00 UTC

Tulu

Danaher 3Q Adj EPS $1.71 >DHR

22. okt 2024, 10:00 UTC

Tulu

Danaher 3Q Net $818M >DHR

22. okt 2024, 10:00 UTC

Tulu

Danaher 3Q Cont Ops EPS $1.12 >DHR

23. juuli 2024, 12:39 UTC

Peamised uudised
Tulu

Danaher Stock Surges. More Than Earnings Are Driving It Higher. -- Barrons.com

23. juuli 2024, 10:05 UTC

Tulu

Danaher 2Q Adjusted Core Revenue Fell 3.5% >DHR

23. juuli 2024, 10:05 UTC

Tulu

Danaher Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Võrdlus sarnastega

Hinnamuutus

Danaher Corp Prognoos

Hinnasiht

By TipRanks

31.35% tõus

12 kuu keskmine prognoos

Keskmine 263.21 USD  31.35%

Kõrge 300 USD

Madal 240 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Danaher Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

13

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

199.15 / 210.53Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

62 / 386 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.